BR0014512A - Tratamento tópico para infecções por estreptococos - Google Patents

Tratamento tópico para infecções por estreptococos

Info

Publication number
BR0014512A
BR0014512A BR0014512-2A BR0014512A BR0014512A BR 0014512 A BR0014512 A BR 0014512A BR 0014512 A BR0014512 A BR 0014512A BR 0014512 A BR0014512 A BR 0014512A
Authority
BR
Brazil
Prior art keywords
topical treatment
therapeutic agent
infections
streptococcal
streptococcal infections
Prior art date
Application number
BR0014512-2A
Other languages
English (en)
Inventor
Vincent Fischetti
Lawrence Loomis
Original Assignee
New Horizons Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Horizons Diagnostics Inc filed Critical New Horizons Diagnostics Inc
Publication of BR0014512A publication Critical patent/BR0014512A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: "TRATAMENTO TóPICO PARA INFECçõES POR ESTREPTOCOCOS". A presente invenção refere-se um método e uma composição para o tratamento tópico de infecções por estreptococos por meio do uso de uma enzima lisina misturada com um veículo adequado para aplicação tópica nos tecidos dérmicos. Os métodos para o tratamento de infecções dermatológicas por estreptococos compreende administrar uma composição compreendendo uma quantidade eficaz de um agente terapêutico, com o agente terapêutico compreendendo uma enzima lisina produzida por bactérias estreptocócicas do grupo C infectadas com um bacteriófago CI. O agente terapêutico pode estar em um veículo farmaceuticamente aceitável.
BR0014512-2A 1999-09-14 2000-01-20 Tratamento tópico para infecções por estreptococos BR0014512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/395,637 US6056955A (en) 1999-09-14 1999-09-14 Topical treatment of streptococcal infections
PCT/US2000/001237 WO2001019391A1 (en) 1999-09-14 2000-01-20 Topical treatment of streptococcal infections

Publications (1)

Publication Number Publication Date
BR0014512A true BR0014512A (pt) 2002-06-18

Family

ID=23563869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014512-2A BR0014512A (pt) 1999-09-14 2000-01-20 Tratamento tópico para infecções por estreptococos

Country Status (12)

Country Link
US (1) US6056955A (pt)
EP (1) EP1212079A1 (pt)
JP (1) JP2003509379A (pt)
CN (1) CN1390135A (pt)
AU (1) AU2617500A (pt)
BR (1) BR0014512A (pt)
CA (1) CA2383038A1 (pt)
IL (1) IL148641A0 (pt)
MX (1) MXPA02002895A (pt)
NZ (1) NZ518059A (pt)
WO (1) WO2001019391A1 (pt)
ZA (1) ZA200202306B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157036A1 (en) * 2002-02-20 2003-08-21 Osborne David W. Topical dapsone for the treatment of acne
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
WO2004064732A2 (en) * 2003-01-16 2004-08-05 New Horizons Diagnostics Corporation The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6335012B1 (en) 1997-10-31 2002-01-01 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth
US6406692B1 (en) * 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6326002B1 (en) 1997-10-31 2001-12-04 New Horizons Diagnostics Corporation Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6277399B1 (en) * 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
WO2001082945A2 (en) * 2000-04-28 2001-11-08 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
WO2002102405A1 (en) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation The use of bacterial phage associated lytic enzymes to prevent food poisoning
AU2002322275A1 (en) * 2001-06-20 2003-01-08 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
JP4849772B2 (ja) * 2001-09-27 2012-01-11 ガンガゲン インコーポレーティッド 免疫原性が低いリシン欠損バクテリオファージ
US6759229B2 (en) * 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
AU2003241279A1 (en) * 2002-03-26 2003-10-13 Biosynexus Incorporated Antimicrobial polymer conjugates
AU2003273257A1 (en) * 2002-08-29 2004-03-19 The Uab Research Foundation Group b streptococcal phage lysin
US20050129711A1 (en) * 2002-11-14 2005-06-16 Janakiraman Ramachandran Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
AP2005003346A0 (en) * 2002-12-10 2005-06-30 Biosynexus Inc Topical anti-infective formulations
US7582729B2 (en) * 2003-05-15 2009-09-01 The Rockefeller University Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
MXPA06001713A (es) * 2003-08-13 2007-01-26 Qlt Usa Inc Composicion de emulsion que contiene dapsone.
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
CN1315532C (zh) * 2004-10-19 2007-05-16 上海新药研究开发中心 复合溶菌酶Lysoamidase喷雾剂及制备方法
JP2008518026A (ja) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー 副腎皮質刺激ホルモンアナログおよびこれに関連する方法
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
DE602006018746D1 (de) * 2005-08-24 2011-01-20 Univ Rockefeller Ply-gbs-lysinmutanten
US20070116749A1 (en) * 2005-11-21 2007-05-24 Grossman Leonard D Method for treatment of cellulitis
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
ES2775825T3 (es) 2008-02-27 2020-07-28 Allergan Inc Dapsona para tratar la rosácea
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US20100029781A1 (en) * 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
US20090304673A1 (en) * 2008-06-10 2009-12-10 Bernd Buchberger Method of Treatment of Inflammatory Diseases
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
CN102198265B (zh) * 2011-03-22 2013-08-28 上海交通大学 应用噬菌体裂解酶降解猪链球菌生物被膜的方法
EP2699253B1 (en) 2011-04-21 2018-03-28 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP3369742B1 (en) 2011-10-05 2020-07-29 The Rockefeller University Dimeric bacteriophage lysins
US9757328B2 (en) * 2012-03-29 2017-09-12 Murami Pharma, Inc. Lysozyme gel formulations
RU2646102C2 (ru) 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
IL235527B2 (en) 2012-05-09 2023-10-01 Contrafect Corp Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
CN102961324B (zh) * 2012-11-16 2014-06-25 沈阳药科大学 一种溶菌酶眼用凝胶剂及其制备方法
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11173163B2 (en) * 2015-08-05 2021-11-16 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US10851401B2 (en) 2016-05-12 2020-12-01 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
WO2019236374A2 (en) 2018-06-04 2019-12-12 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1542848A (en) * 1975-06-11 1979-03-28 Searle & Co Anti-mycotic pharmaceutical compositions containing enzymes
FR2357246A1 (fr) * 1976-07-09 1978-02-03 Martinez Gerard Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique
WO1988002781A1 (en) * 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
RU2064299C1 (ru) * 1993-12-13 1996-07-27 Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии Препарат для лечения мастита крупного рогатого скота "лизомаст"
RU2103991C1 (ru) * 1995-08-14 1998-02-10 Научно-производственное объединение "Иммунопрепарат" Средство для лечения стрептококковых заболеваний
US5997862A (en) * 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections

Also Published As

Publication number Publication date
IL148641A0 (en) 2002-09-12
US6056955A (en) 2000-05-02
JP2003509379A (ja) 2003-03-11
WO2001019391A1 (en) 2001-03-22
AU2617500A (en) 2001-04-17
CA2383038A1 (en) 2001-03-22
NZ518059A (en) 2003-09-26
EP1212079A1 (en) 2002-06-12
CN1390135A (zh) 2003-01-08
ZA200202306B (en) 2002-12-24
MXPA02002895A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0110420A (pt) Agonistas muscarìnicos
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
BR0011286A (pt) Preparado farmacêutico com a substância ativa diamorfina e seu emprego em um processo para tratamento de vìcio em ópio
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR9916076A (pt) Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
BR9814721A (pt) "uso de polióis, dispositivo apropriado para o tratamento ou profilaxia de infecção da mucosa causada por levedura em mamìferos, processo para tratamento terapêutico ou profilático de mamìferos sofrendo de ou sendo submetidos a um risco aumentado de infecção da mucosa causada por levedura, composição para uso neste trtatamento, e, preparação farmacêutica para uso no tratamento profilático ou terapêutico sistêmico ou tópico de infecções da mucosa causadas por levedura."
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
DE69530124D1 (de) Liposomale antibakterielle zusammensetzung mit geringer festigkeit
BR9708706B8 (pt) composição farmacêutica para administração intravenosa a um paciente
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
AU2002216748A1 (en) Method of treatment of seborrheic dermatitis
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0204911A (pt) Composição cosmética destinada ao tratamento das fibras queratìnicas humanas que compreende um silicone aminado particular, processo de preparação de uma composição. processo e dispositivo com dois compartimentos ou 'kit' para a descoloração ou a deformação permanente das fibras queratìnicas humanas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.